Clinical trial: New drug combination reduces anemia in rare blood disorder
A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the ...
Hosted on MSN1mon
Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta
Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan) for treating adults with paroxysmal nocturnal haemoglobinuria (PNH).
News Medical3y
Ultomiris 100mg/ml
Read before using this medicine. Ultomiris contains the active ingredient ravulizumab rch. For more information, see Section 1. Why am I using Ultomiris? in the full CMI. 2. What should I know ...
Business Wire1mon
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
In PNH patients experiencing substantial extravascular hemolysis while receiving ravulizumab, zaltenibart monotherapy resulted in sustained clinically meaningful improvements in both hemoglobin ...